OUR TEAM
Strong scientific, clinical, and drug development expertise.
Six co-founders spanning operations, translational science, and clinical neuro-oncology — with 120+ years of combined experience across Genentech, Roche, Dana-Farber, Harvard, and Stanford.
Collectively, Braindoot’s founding and scientific leadership team brings more than 100 years of combined experience across translational science, medicinal chemistry, neuro-oncology, clinical development, biotechnology operations, strategic partnerships, and company building.
The team has founded biotechnology companies, advanced therapeutic programs from discovery through clinical development, led clinical trials, built operational organizations, and developed platform technologies that form the foundation of Braindoot’s precision brain-targeting strategy.
Geeta Singh, MBA
20+ years in process development, GMP operations, tech transfer, and process development.
Read More →
Karthika Nair, MSc
10+ years in biotech research, operations, and clinical readiness.
Read More →
Pradip K. Majumder, PhD
25+ years in oncology research and drug development-driven entrepreneurship.
Read More →
Ahmed Aman, PhD
25+ years leading biotech and academic translational research.
Read More →
Dr. Santosh Kesari, MD
25+ years in neuro-oncology, translational medicine, and precision therapeutics.
Read More →
Dr. Fabio Iwamoto, MD
15+ years in clinical neuro-oncology, translational medicine, and precision oncology.
Read More →Founders who’ve built, translated, and treated — not just theorized.
From Genentech process development to Stanford neuro-oncology clinics, this team has taken drugs from bench to bedside before. Braindoot is built to do it again — for the brain.